Agios Q2 2026 revenue rises to $44.7 million; net loss narrows to $100.7 million
Agios reported second-quarter 2026 total revenue of $44.7 million, up from $12.5 million a year earlier, and a net loss of $100.7 million, down from $112.0 million. The company said the FDA granted Priority Review to its mitapivat sickle cell disease application, with a PDUFA goal date of November 1, 2026, and that cash and marketable securities were $964.8 million at June 30, 2026, for shareholders, higher revenue and a smaller loss were offset in part by higher R&D spending and the decision to stop development of tebapivat.
Key points
- Total revenue was $44.7 million in Q2 2026, versus $12.5 million in Q2 2025; U.S. net revenue was $40.9 million.
- Net loss was $100.7 million, or $1.69 per share, versus $112.0 million, or $1.93 per share, a year earlier.
- R&D expenses rose to $100.8 million from $91.9 million, driven mainly by a $25.0 million up-front payment to Oscotec for cevidoplenib.
- FDA granted Priority Review to the mitapivat sNDA in sickle cell disease, with a PDUFA goal date of November 1, 2026; Agios will not advance tebapivat in LR-MDS or sickle cell disease.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.